Poster note: Target discovery program in systemic sclerosis
Novel candidate drug targets for systemic scleroderma were identified using RNAi in phenotypic assays in scleroderma patient-derived fibroblasts…
This poster outlines a study to identify and validate novel candidate drug targets using RNAi in phenotypic assays in systemic sclerosis patient-derived fibroblasts.
A high throughput primary screen measuring the reversion of myofibroblasts was developed to screen Charles River’s SilenceSelect® adenoviral shRNA library (~21,000 shRNAs screened). Inhibition of aSMA mRNA expression was measured via fluorescence in situ hybridization (FISH), and ~550 shRNAs were selected for rescreen. Follow on 2D and 3D validation assays including gel contractility, impedance and skin equivalent (SE) are described.
This poster note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Cell-based assays market set to exhibit CAGR of 8.5 percent
- Under the microscope: CROs and microplate reader requirements
- Charles River Laboratories continues commitment to oncology drug discovery
- Charles River to present collaborative methods at Neuroscience 2018
- Charles River and Distributed Bio enter exclusive partnership to create an integrated antibody discovery and development platform